Disc Medicine (NASDAQ: IRON) Stock Soars on Positive Bitopertin Trial Results and Analyst Upgrade
BMO Capital has raised its price target for Disc Medicine to $120 from $100, maintaining an Outperform rating on the biotechnology stock. Positive Phase 3 clinical trial results for bitopertin in erythropoietic protoporphyria met both primary endpoints, demonstrating efficacy and a favorable…